Labor Market Pulse · Life Sciences · October 2026
Life Sciences Labor Market Report: Longview, TX MSA — October 2026
Longview life sci pay diverges from a tightening state market.
Longview unemployment eased to 4.6% even as statewide biopharma postings jumped 53% year-over-year, while local Regulatory Affairs pay fell to $95,473 against a national shortage of regulatory talent.
Free archive edition. Published by WageScape as sent to subscribers; data as of October 2026.
Key indicators
- Longview MSA unemployment: 4.6% — Down from 5.0% in August; vs 4.2% national
- Metro employment growth: +600 jobs YoY — 124.7k total nonfarm jobs, Sept 2026
- Texas biopharma postings growth: +53% YoY — Jan-Aug 2026, outpacing local hiring capacity
- National biopharma layoffs: -90% YoY — Q3 2026, signals hiring momentum returning
Key takeaways
Biostatistician pay here is outrunning the national rate.
Metro median of $139,166 sits above the national $131,958, a reversal from most Longview life sci roles. That premium may reflect scarcity, worth confirming before assuming it signals broader market heat.
Regulatory Affairs compensation is softening against a tightening national market.
Metro and national Regulatory Affairs Specialist pay both declined this month even as national commentary flags regulatory talent as the hardest life sci role to fill in 2026. A local pullback in advertised pay during a national shortage may understate the retention risk building beneath the surface.
Local job growth near zero complicates the build-versus-outsource math.
With only 600 net jobs added locally over the year against a 53% statewide surge in biopharma postings, Longview employers face a shrinking local bench for specialized hires. That imbalance strengthens the case for CRO or CDMO partnerships on roles where in-market sourcing already looks constrained.
Validation Engineer demand is rising while national pay holds flat.
Metro pay moved up moderately to $104,143, converging toward the $106,478 national figure. Convergence suggests Longview employers are closing a compensation gap that previously limited competitiveness for manufacturing and quality talent.
Median advertised pay by role — Longview, TX MSA
| Role | 25th percentile | Median advertised pay | 75th percentile | Metro trend | National median |
|---|---|---|---|---|---|
| Research Scientist * | $82,765 | $123,070 | $131,979 | Significant increase | $130,339 |
| Clinical Research Associate * | $57,977 | $78,893 | $95,462 | Moderate increase | $90,065 |
| Lab Technician * | $38,082 | $45,670 | $49,588 | Stable | $47,840 |
| Regulatory Affairs Specialist * | $70,793 | $95,473 | $116,373 | Moderate decline | $103,780 |
| Clinical Data Manager * | $96,453 | $122,953 | $135,700 | Stable | $123,653 |
| Biostatistician * | $98,485 | $139,166 | $160,691 | Moderate increase | $131,958 |
| Validation Engineer * | $82,756 | $104,143 | $112,977 | Moderate increase | $106,478 |
* State-level figure shown where metro postings were too few.
WageScape's median is calibrated to correct for spurious low-value postings (reported as the 60th percentile of raw advertised pay). Download: CSV · JSON
Local market conditions
Longview MSA unemployment eased to 4.6% in September from 5.0% in August, with nonfarm employment at 124.7 thousand — up only 600 positions year-over-year, pointing to a labor market stabilizing but not expanding meaningfully. Statewide, Texas biopharma job postings surged 53% year-over-year through August while national lab and R&D vacancy rates hit 23.2% in top markets, suggesting Longview employers compete against a state-level talent pull far outpacing local job growth.
What it means
Flat local headcount growth alongside statewide biopharma posting surges means Longview-based R&D and quality roles likely draw candidates toward Houston, Austin, or Dallas postings offering deeper talent pools and higher advertised pay — a dynamic reinforced by Research Scientist pay sitting $7,269 below the national median locally. With national quit rates at just 1.9% and nearly a quarter of the life sciences workforce aged 55 or older, losing a single credentialed specialist in regulatory affairs or clinical operations carries outsized replacement risk in a market this thin. Consider evaluating succession coverage for scientific and quality leadership roles now, before a departure forces a build-versus-outsource decision under time pressure.
Looking ahead
Early indicator: Watch whether Longview's modest unemployment decline (5.0% to 4.6%) continues through October data releases in mid-November. A reversal would tighten an already thin local labor supply for quality and manufacturing roles.
Emerging pressure point: Texas biopharma postings are up 53% year-over-year statewide while Longview employment barely moved. Track whether Dallas, Houston, or Austin compensation increases begin pulling credentialed Longview talent toward larger metros.
Worth watching: Regulatory Affairs pay fell both locally and nationally this month despite national reports citing regulatory talent as the toughest hire of 2026. A further decline alongside persistent vacancy reports would signal a disconnect between advertised pay and actual hiring difficulty.
Potential inflection point: National biopharma layoffs are down 90% year-over-year and M&A activity is up 63% in H1 2026, conditions that typically precede headcount expansion. Monitor whether Longview-based employers begin posting more clinical or manufacturing roles as consolidation activity plays out regionally.
Sources
- Texas Workforce Commission — Longview MSA unemployment rate and nonfarm employment figures for September 2026
- Texas life sciences labor market research — Texas biopharma job postings surged 53% YoY Jan-Aug 2026
- Biopharma industry labor market survey — National quit rate at 1.9% and life sciences workforce aging data
- National life sciences labor market research — Regulatory affairs cited as hardest-to-fill pharma role in 2026
- Biopharma industry labor market research — National biopharma layoffs down 90% YoY, M&A activity up 63% H1 2026
- Life sciences labor market research — Lab/R&D vacancy reached 23.2% across top 13 U.S. life sciences markets Q1 2026
Methodology
Advertised pay from active employer job postings, not survey data. WageScape's median is calibrated to correct for spurious low-value postings: distribution analysis shows roughly the lowest 10% of raw values are erroneous entries, so the reported median is the 60th percentile of raw advertised pay. WageScape observes 98% of U.S. job openings daily.
Free to read and cite with attribution to WageScape. Terms of use.